Avid Bioservices Inc (CDMO)

[freethemice]

I found two more second-line NSCLC trails and have added them to a new table which also lists the ECOG
performance status (PS), and the stage III/IV percentages. Note that the Fossella et al, 2000 trial is fairly similar
in MOS, PS, and stage III/IV to the Peregrine trial. Not all data was reported and so there are some blanks in the table.


I found some survival plots which show the difference due to PS and disease extent (stage III or IV).
These are from the Kindler et al, 2010 trial of Avastin and gemcitabine compared with placebo and gemcitabine
in pancreatic cancer. You can see Avastin added nothing to gemcitabine, i.e. it acted like a placebo.
These show you how the mixture of PS and disease extent could make quite a difference in survival.